Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading ARTL daily closes…
Loading price history…
Pipeline assets
ART27.13
Phase 2 · Active
Target cannabinoid GPCR
Partnerships Exclusive worldwide license from NEOMED Institute (adMare Bioinnovations)
Indications
Cancer anorexia cachexia syndrome(Phase 2)
Status note Phase 1b/2a CAReS study of cancer-related anorexia; filing reports an interim analysis of the ongoing Phase 2a portion. Filing describes a synthetic oral formulation developed for this use. 10-K fallback classifies the program as a cannabinoid GPCR agonist.
Status note IND application submitted with FDA study-may-proceed notice received July 8, 2024; CIPN prioritized as initial indication; diabetic neuropathy also explored. 10-K fallback classifies the program as a cannabinoid GPCR agonist.
ART12.11
Discovery · Active
Partnerships n/a (wholly owned)
Indications
Anxiety(Discovery)
Status note Internal discovery research initiative; CBD co-crystal composition. Filing states an anxiety strategy became a priority based on results; no clinical stage stated.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.